Key result
Implantation of a continuous-flow LVAD in an 8-year-old child with anthracycline-induced cardiomyopathy served as a successful bridge to recovery, allowing device explantation after 3 months.
Case Report (n=1)
No
Answers are grounded in this paper and cite their sources.
This case demonstrates that continuous-flow LVADs can be successfully used as a bridge to recovery in pediatric patients with acute anthracycline-induced cardiomyopathy and viral myocarditis.
This report describes an 8-year-old child with acute anthracycline-induced cardiomyopathy triggered by human herpesvirus 6 and the subsequent implantation of an intracorporeal continuous-flow left ventricular assist device (LVAD) and the process to discharge the child from the hospital. After barely 3 months on mechanical support, the device was explanted after thorough examination. Experiences regarding LVAD removal are limited, and no guidelines for echocardiographic and hemodynamic criteria for LVAD removal in children have been published thus far. We present our institutional algorithm for device selection, surveillance in an ambulatory setting, and testing for myocardial recovery, as well as our criteria for LVAD explantation in children.
No takes yet. Share an insight, caveat, or question.
Cavigelli-Brunner et al. (2014) conducted a case report in Acute anthracycline-induced cardiomyopathy triggered by human herpesvirus 6 (n=1). Intracorporeal continuous-flow left ventricular assist device (LVAD) was evaluated. Implantation of a continuous-flow LVAD in an 8-year-old child with anthracycline-induced cardiomyopathy served as a successful bridge to recovery, allowing device explantation after 3 months.
Synapse has enriched 10 related papers. Consider them for comparative context: